AHEAD OF THE UPGRADE:
Rodman & Renshaw upgrades Mkt Perform to Mkt Outperform. Target $13. Rodman & Renshaw upgrades TPTX to Outperform from Market Perform and sets a $13 tgt, based on their lead molecule, tezampanel, as a promising candidate for the treatment of migraine headache and believe the peak market potential for tezampanel could exceed $850 mln
TORREYPINES THERAPEUTICS
(TPTX)
7.20
+0.55 (+8.27%)
it took a month....but we got that 5%+ gain!
original BUY RECO post:
http://www.buyonthedip.com/2007/04/oddball-friday-here-goes.html
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment